$LQDA

JEFFS ROGER sold $2.5M of LQDA

JEFFS ROGER (Chief Executive Officer) sold 35,249 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52, $2.52M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · JEFFS ROGER
Published Jul 15, 2026, 12:07 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 15, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The newest actionable element is the specific trade size, price range, and confirmation that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may treat this as a routine 10b5-1 sale, with limited fundamental implications, but it can marginally influence short-term sentiment.

03

What to watch

The filing does not disclose reasons for the sale, and the weighted-average price range ($71.39 to $71.52) suggests execution around prevailing market levels rather than a distressed sale.

Relevance 5/10Novelty 4/10Timing: SEC Form 4 filed 2026-07-14 for sales executed 2026-07-13

Background

The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp, reporting CEO Jeffs Roger’s open-market sale of shares.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia CEO Jeffs Roger sold 35,249 shares in open-market trades at about $71.51, per a newly filed SEC Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief unless paired with other company-specific catalysts.

Evidence & confidence

The filing is primary-source and time-stamped, but the trades are explicitly under a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

Market effects

Minimal, as the disclosure is company-specific insider activity without sector-wide information.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with periods of reduced confidence or liquidity needs, so traders may still watch for follow-on selling patterns.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider transaction disclosure.

  • Jeffs Roger

    CEO and director reporting the sale of shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient